A Multicenter, Open-label, Phase 1b/2 Study to Evaluate the Safety and Efficacy of RX-0201 in Combination With Everolimus to Treat Subjects With Advanced Renal Cell Carcinoma

Basic eligibility criteria:
Please contact the study coordinator for additional eligibility information.

Inclusion Criteria:
Males and females ? 18 years of age at screening
Histological or cytological diagnosis of renal cell cancer with a clear-cell component
Measurable or evaluable disease defined by Response Evaluation Criteria for Solid Tumors (RECIST) ver. 1.1
Must have received at least one course of therapy with a VEGFR-targeting tyrosine kinase inhibitor (eg, sorafenib, sunitinib, axitinib, pazopanib or tivozanib) and progressed within 6 months of planned first dose of study treatment
No more than 3 prior treatments of systemic therapy for renal cancer
ECOG performance status of 0,1 or 2
Life expectancy > 3 months

Exclusion Criteria:
Brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery and stable for at least 3 months before planned first dose of study drug
Radiation therapy for bone metastasis within 2 weeks, any other external radiation therapy within 4 weeks before planned first dose of study drug. Systemic treatment with radionuclides within 6 weeks before planned first dose of study drug. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible
Prior treatment with everolimus, or any other specific or selective TORC1/PI3K/AKT inhibitor (eg, temsirolimus)
Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before planned first dose of study drug
Receipt of any type of anticancer antibody (including investigational antibody) within 4 weeks before planned first dose of study drug
Taking strong inducers or inhibitors of CYP450s for subjects receiving everolimus
Chronic treatment with corticosteroids or other immunosuppressive agents
Concomitant anticoagulation at therapeutic doses with oral anticoagulants or platelet inhibitors
Subjects with a known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus) or to its excipients
Major surgery within 2 months before planned first dose of study drug
Myocardial infarction within the previous 6 months before planned first dose of study drug
Active infection requiring parenteral antibiotics within 2 weeks before planned first dose of study drug
Diagnosis of another malignancy within 2 years before planned first dose of study drug, except for superficial skin cancers, or localized, low grade tumors
Prior or current history of hepatitis B, hepatitis C or human immunodeficiency virus
Sexually active fertile subjects (male and female) must agree to use medically accepted methods of contraception during the course of the study and for 30 days after the last dose of study treatment